Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated
